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Abstract.
Background: Dementia, including Alzheimer’s disease (AD), is one of the most burdensome medical conditions. Usu-
ally, the reviews that aim at calculating the prevalence of dementia include estimates from studies without assessing their
methodological quality. Alzheimer’s Disease International (ADI) proposed a score to assess the methodological quality of
population-based studies aimed at estimating the prevalence of dementia. During the last three years, the European Com-
mission has funded three projects (Eurodem, EuroCoDe, and ALCOVE) in order to estimate the prevalence of dementia in
Europe.
Objective: The aim of this study was to perform a systematic review and meta-analysis of data on the prevalence of dementia
in Europe derived from studies that included only subjects with a diagnosis of dementia according to the DSM IV criteria,
and that had a high quality score according to ADI criteria.
Methods: We considered the studies selected by the two projects EuroCoDe (1993–2007) and Alcove (2008–2011), and we
performed a new bibliographic search. For the systematic review, we only selected the subset of articles that included subjects
with a diagnosis of dementia according to the DSM IV criteria. The studies were qualitatively assessed using the ADI tool.
Results: The meta-analysis considered 9 studies that were carried out in Europe between 1993 and 2018 including a total of
18,263 participants, of which 2,137 were diagnosed with dementia. The prevalence rate standardized for age and sex resulted
7.1%.
Discussion: This is the first systematic review on the prevalence of dementia in Europe considering only high-quality studies
adopting the same diagnostic criteria (i.e., DSM IV).
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INTRODUCTION
Dementia is increasingly indicated as a public
health priority, given the lack of curative treatments
and the ongoing sociodemographic transformations
of our populations. In Europe, the number of
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dementia cases is estimated to increase from 7.7 mil-
lion in 2001 to 15.9 million in 2040 [1]. Accordingly,
the costs of dementia are forecasted to raise in the
whole European continent by about 43% between
2008 and 2030 to over 250 billions D [2]. In this
evolving scenario, reaching an adequate knowledge
of the epidemiology of the dementia phenomenon is
essential to inform and sustain dedicated social and
healthcare policies. In particular, accurately estimat-
ing its prevalence is a crucial step in order to plan and
calibrate any targeted action aiming at mitigating its
clinical and socioeconomic impact.
In this regard, the European Commission funded,
in the last decades, three projects to estimate the
prevalence of dementia in Europe. The first one, Euro-
dem, was a concerted action designed to strengthen,
develop, and provide epidemiological data on demen-
tia in Europe [3, 4]. In 1991, the Eurodem group
first published a pooled analysis of original data
from studies reporting the prevalence of dementia
between 1980 and 1990 in some specific Euro-
pean countries [3]. The review included 12 studies
enrolling participants that were examined and diag-
nosed with dementia according to the DSM III, DSM
III-R, CAMDEX, AGECAT, ICD-9 criteria, or sim-
ilar definitions [3]. A second review was published
in 2000, considering 11 population-based studies,
carried out in Europe between 1991 and 1997, recruit-
ing participants diagnosed with dementia according
to the DSM III-R, CAMDEX, AGECAT criteria, or
equivalent ones [4]. The review reported a 6.4% age-
standardized prevalence in the population aged ≥65
years [4]. The second project, EuroCoDe (European
Collaboration on Dementia), was part of the EU’s
2005 work plan of the Community public health
program, and a literature review was performed to
estimate the prevalence rate of dementia. This review
included 17 population-based prevalence studies per-
formed in Europe between 1989 and 2005, and that
included subjects diagnosed with dementia according
to the DSM III-R, DSM IV, CAMDEX, and ICD-
10 clinical criteria [5]. The third project, ALCOVE
(Alzheimer’s Cooperative Valuation in Europe), con-
cerned various topics including the epidemiology and
prevalence of dementia. The review performed within
the ALCOVE project to estimate the prevalence
of dementia included 12 population-based studies
performed in Europe between 2008 and 2011 [6].
The results from both the reviews performed by
the EuroCoDe and the ALCOVE projects have not
yet been published in any scientific peer-reviewed
journal [5, 6].
A first, relevant knowledge gap concerning the
prevalence of dementia in Europe is therefore rep-
resented by the fact that the currently available
estimates are now outdated and have been obtained
by considering older diagnostic criteria. A second,
important issue is constituted by the methodologi-
cal quality of this body of evidence. In particular,
most of the analyses conducted on this topic have
not adequately considered the methodological quality
of the pooled studies. As a result, most of estimates
are based on data of weak quality. It is noteworthy
that in 2009 the Alzheimer’s Disease International
(ADI) proposed a score to assess the methodological
quality of population-based studies aimed at estimat-
ing the prevalence of dementia. The score focuses
on the following issues: sample size, study design,
response rate, and type of diagnostic criteria [7]. In
the ALCOVE project, the ADI tool was used; nev-
ertheless, to date, none of the published studies used
this tool to identify the evidence methodologically
worthy to be included in pooled analysis on dementia
prevalence.
Based on these considerations, the aim of the
present study was to provide an updated (from 1993
to 2018) on the prevalence of dementia, focusing only
on the studies with a higher methodological quality
and including subjects diagnosed using the DSM IV
criteria for dementia.
METHODS
Selected studies from EuroCoDe (1993–2007)
and ALCOVE (2008-15 September 2011) project
were resumed. A further structured search on MED-
LINE/PubMed was performed by a researcher with
experience in bibliographic searches to retrieve all
studies published between 16 September 2011 and
9 July 2018. For this search, we used the same
structured string used in both the EuroCoDe project
and the ALCOVE project, including the following
terms: ((“Dementia”[Mesh] OR “Alzheimer dis-
ease”[Mesh] OR “Dementia, Vascular”[Mesh] OR
“Lewy Body Disease”[Mesh] OR “Frontotemporal
dementia”[Mesh]) AND (“Prevalence”[Mesh] OR
“Incidence”[Mesh] OR “Epidemiology”[Mesh]))
OR (((“Dementia”[TIAB] OR “Alzheimer dis-
ease”[TIAB] OR “dementia, vascular”[TIAB] OR
“Lewy Body Disease”[TIAB] OR “Frontotemporal
dementia”[Mesh]) AND (“Prevalence”[TIAB] OR
“Incidence”[TIAB] OR “Epidemiology”[TIAB]))
NOT MEDLINE[SB]).
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The titles and abstracts of retrieved studies were
analyzed, and all studies considered relevant and per-
tinent to the topic of the review were selected. Each
abstract was assessed by two independent reviewers
(I.B., N.V.). Disagreements were solved by discus-
sion, consensus, or involving a third reviewer (E.L.).
The full texts of all selected studies were collected.
The same predefined inclusion criteria adopted by
both the EuroCoDe and the ALCOVE projects [5, 6]
were applied to these selected studies.
Thus, only 1) community-based studies, 2)
enrolling at least 300 participants, 3) using standard-
ized diagnostic criteria, 4) with a response rate higher
than 50%, 4) reporting raw prevalence data, and 5)
performed in European countries, were selected. We
further excluded all studies that did not use the DSM
IV for the diagnosis of dementia [8], and the studies
that did not report data separately for age classes and
sex.
All the studies selected for both our review and for
the EuroCoDe and ALCOVE projects were qualita-
tively assessed, and data were extracted.
The methodological quality was independently
evaluated and scored by two reviewers (I.B., N.V.)
using the ADI tool reported in Table 1. Even-
tual disagreements in the quality assessment process
were solved by discussion, consensus, or involving
a third reviewer (E.L.). Two independent review-
ers (F.M. and E.L.) extracted the following data
from the retrieved articles: bibliographic references,
country, year(s) in which the study was carried
out, age-classes, number of participants, number of
dementia cases, crude prevalence rate along with
its 95% confidence intervals (CIs). The clinical and
instrumental procedures adopted for the diagnosis of
dementia (screening test, blood tests, clinical exam-
ination, informant review, medical records, brain
imaging) were also analyzed. The median qual-
ity score was calculated to define the reference
cut-off to define “highest quality” studies in our
review. Only studies that resulted as having an ADI
score ≥ to the median value were included in this
systematic review.
A meta-analysis of the age- and sex-specific
prevalence rates of dementia observed in the nine
considered studies was conducted. All analyses were
carried out using Stata (version 14.0). Meta-analyses
were performed adopting a specific Stata module,
Metaprop, designed to perform meta-analyses of
proportions in Stata [9]. Overall estimates were
calculated with random effects models and a test
for heterogeneity was applied using chi-square and
Table 1
Quality assessment tool proposed by the ADI in 2009 [7]
An overall quality score was derived by summing scores for the
following elements:
Sample sizes
<500 0.5 points
500–1499 1 point
1500–2999 1.5 points
≥3000 2 points
Design
Two phase study with no sampling of screen
negatives
0 points
Two phase study with sampling of screen
negatives but no weighting back
1 point
One phase study or two phase study with
appropriate sampling and weighting
2 points
Response proportion
<60% 1 point
60–79% 2 points
≥80% 3 points
Diagnostic assessment
Inclusion of multidomain cognitive test
battery, formal disability assessment
informatics interview and clinical interview
1 point each
the I2 statistics. The random effects meta-analysis
model was chosen to take account of between
study heterogeneity of the included studies, so
the summary effect was a mean estimate of all
effects [10].
A direct standardization according to sex and age-
class was also performed, using as a reference the
structure of the European population as to January
1, 2016 [11]. Confidence intervals were calculated
when not reported in the publication. The following
formula was used to calculate the 95% CIs, assuming
a Poisson distribution of the phenomenon: π ± 1,96√
π (1- π)/n, where π was the prevalence and n the
number of participants [12].
RESULTS
Study selection
The EuroCoDe project retrieved 194 records of
studies published in the years 1993–2007 through the
bibliographic searches [5], of which 31 were selected
for inclusion in the collaborative analysis.
The predefined inclusion criteria were applied
to selected studies, and 17 met such criteria and
were then included in the review [5]. Only three
among these studies used the DSM IV clinical crite-
ria for diagnosing dementia and were thus eligible for
inclusion in our systematic review [13–15].
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The bibliographic searches performed by the
ALCOVE project identified 1,097 records of studies
published from 2008 to 2011, out of which 14 were
selected based on their relevance and pertinence to the
topic of review. After applying the predefined inclu-
sion criteria, 12 studies were included in the review
[16–27]. Only nine of them were eligible for inclu-
sion in our systematic review, as two did not use the
DSM IV criteria [26, 27] and one did not report data
separately for age classes and sex [22].
For our systematic review, we updated the bibli-
ographic search to include studies published up to
2018. A total of 3,427 records were identified, out
of which nine were selected for inclusion on the
prescreening and the application of the predefined
inclusion criteria [28–36]. Two articles were further
excluded as they did not use the DSM IV criteria [28,
32], and four because data were not report separately
for age classes and sex [31, 34–36], thus leaving only
three studies were included among the 3,427 records
identified [29, 30, 33].
Figure 1 reports the flow diagram of the biblio-
graphic searches from each considered source (i.e.,
EuroCoDe, ALCOVE, and our bibliographic search).
Quality assessment
Table 2 reports the main characteristics of the 15
studies included in this systematic review (three from
EuroCoDe, nine from ALCOVE, three from our revi-
sion). Their quality score, assessed with the ADI
tool, ranged from 4.5 to 10.5, with a median value
of 7 (Table 2). We decided to include in the meta-
analysis only the prevalence rates from the studies
with a quality score ≥7. This led to the inclusion in
the analysis of nine studies [13–15, 17, 20, 24, 29, 30,
33]. These studies were published between 2002 and
2015 and were carried out in Europe in the 1999–2010
period. Specifically, three studies were carried out in
Italy [13, 14, 33], three in Spain [15, 20, 29], one in
the United Kingdom [17], one in Luxembourg [30],
and one in Sweden [24]. A total of 18,263 partici-
pants were enrolled in the included studies, and 2,137
subjects were diagnosed with dementia.
All subjects, in the included studies, underwent a
complete work-up for dementia performed by physi-
cians. Clinical examinations, informant reviews and
medical records analysis were carried out in all
included studies. The Mini-Mental State Examina-
tion [13–15, 17, 20, 24, 33], the CERAD-NP-plus bat-
tery [30], or the seven-minute screen neurocognitive
battery [29] were used as screening tests.
Prevalence of dementia
Table 3 reports the crude prevalence data, sepa-
rately for age classes and sex, documented by the
selected studies and the pooled estimate from the
meta-analysis. Data of participants aged ≥90 years
were aggregated.
Two of the studies considered for our meta-analysis
[24, 33] included a significant subgroup of institu-
tionalized subjects reporting respectively a 39.1%
(350/895) [24] and a 14.3% (357/2,504) of the total
population [33] but only the last study reported the
number of cases of dementia (n = 272) [33]. Most
of the included studies show that the prevalence
of dementia increases with age and is higher in
women as compared to men. Specifically, the pooled
prevalence estimates from the meta-analysis for the
age-group 65–69 years, 70–74 years, 75–79 years,
80–84 years, 85–89 years, and ≥90 years were 1.1%,
2.2%, 5.6%, 13.3%, 26.4%, and 38.9% in women.
In men, the pooled prevalence estimates from the
meta-analysis for the age-group 65–69 years, 70–74
years, 75–79 years, 80–84 years, 85–89 years, and
≥90 years were 0.9%, 2.1%, 4.6%, 9.0%, 13.9%, and
31.2% (see Table 3).
On 12 heterogeneity tests performing 8 showed
a significant variability from the age class ≥75 for
men and women with a range included between
54% (age ≥90 men) and 93% (age ≥90 women) the
pooled estimate from the meta-analysis of dementia
in Europe resulted 12.4% in subjects aged >65 years
(95% CI 7.6%–17.2%) (Fig. 3), while the age- and
sex-standardized prevalence rate resulted 7.1%. We
also performed a sensitivity analysis excluding only
the institutionalized population (dementia cases and
not; n = 357) of the Lucca’s study [33]. This meta-
analysis allows to calculate a new pooled prevalence
of dementia in Europe (1865/17906 = 9.3%) (95% CI
6.5%–12.0%). Finally, we compared our prevalence
data with those produced in the two studies published
in the Eurodem project [3, 4] All studies reported
an increase of dementia prevalence with increasing
of age. However, our study also showed that such
increase tends to start earlier in women (80–84 years)
than in men (85–89 years) (Fig. 2).
DISCUSSION
To our knowledge, this is the first systematic review
on the prevalence of dementia in Europe considering
only high-quality studies adopting the same diagnos-
tic criteria (i.e., DSM IV).
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Fig. 1. Flow chart of systematic review process.
Our estimates, standardized by age class and sex,
resulted higher than those provided by Lobo et al.
(7.1% versus 6.4%) [4]. In particular, the prevalence
rates among women aged >80 years were higher than
those reported in the Eurodem study (1980–1990)
[3] and Lobo’s study [4] (see Fig. 2). Similarly, the
specific prevalence rates in men aged >85 years were
higher than those previously reported [4] (see Fig. 2).
Such higher estimates could be partially due to the
inclusion in this systematic review of two studies
that enrolled also institutionalized subjects aged >80
years [24, 33] that usually show a higher frequency
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Table 2
Characteristics of included studies
Author Year∗ Country Age No. of No. of cases Crude prevalence ADI Total
range Participants of dementia rate (IC 95%) Score
#Ravaglia et al. [13] 1999 Italy ≥65 1016 60 5.9 (4.3–7.8) 7
#Tognoni et al. [14] 2000 Italy ≥65 1600 100 6.2 (5.1–7.4) 7.5
#Gasco`n-Bayarri et al. [15] 2002 Spain ≥70 1754 165 9.4 (8.0–10.8) 9.5
Ferna`ndez et al. [16] 2004 Spain ≥65 1931 175 9.1 (7.8–10.3) 5.5
#Fish et al. [17] 2003 UK 65–84 1699 88 5.2 (4.2–6.3) 7.5
Gavrila et al. [18] 2003–2005 Spain 65–96 1074 56 5.5 (4.3–7.1) 5.5
#Bermejo-Pareja et al. [20] 1994–1995
(baseline)
1997–1998
(follow-up)
Spain ≥65 5278 306 5.8 (5.2–6.5) 9
Spada et al. [19] 2005 Italy 60–85 280 20 7.1 (4.1–10.1) 4.5
Nunes et al. [21] 2003–2004 Portugal 55–79 1146 31 2.7 (1.9–3.8) 4.5
Adelman et al. [23] 2007–2008 UK ≥60 436 36 8.3 (5.7–10.8) 5
#Mathillas et al. [24] 2000–2002
and
2005–2007
Sweden ≥85 895 287 32.1 (29.0–35.1) 7
Virue´s-Ortega et al. [25] 1990–2003 Spain ≥75 546 49 9.0 (6.6–11.4) 6
#Tola-Arribas et al. [29] 2009–2010 Spain 65–104 2170 184 8.5 (7.3–9.7) 8.5
#Lucca et al. [33] 2002–2010 Italy ≥80 2504 894 35.7 (33.9–37.6) 10.5
#Perquin et al. [30] 2008 Luxembourg >64 1377 53 3.8 (2.8–4.8) 8
∗year in which the study was carried out. #Studies included in the meta-analysis.
Table 3
Prevalence of dementia (per 100 pop.) in selected European studies, according to sex and age-class [% (n/tot)] and pooled prevalence
estimates meta-analysis of generated from Poisson random effect model
Population 65–69 70–74 75–79 80–84 85–89 ≥90
Ravaglia [13] Italy women – 2.1 (3/143) 3.2 (4/125) 11 (9/82) 37 (20/54) 70.6 (12/17)
men 1.4 (2/143) 1.4 (2/143) 0.8 (1/125) 1.2 (1/83) 5 (2/40) 57.1 (4/7)
Tognoni [14] Italy women 0.7 (2/286) 1.6 (4/250) 6.7 (15/224) 13.6 (13/96) 25.5 (25/98) 28.2 (13/46)
men 1.4 (3/214) 1.1 (2/182) 7.4 (11/149) 5.4 (3/55) 10.6 (5/47) 26.7 (4/15)
Gasco`n- Bayarri [15] Spain women – 2.5 (10/405) 6.4 (18/280) 14.6 (25/171) 28.6 (30/105) 48.3 (28/58)
men – 3.2 (11/344) 4.7 (10/212) 12.8 (14/109) 19.6 (9/46) 41.6 (10/24)
Fish [17] UK women – – – – – –
men 0.8 (4/500) 3.9 (23/590) 9.4 (43/457) 15.4 (18/117) – –
Bermejo-Pareja [20] Spain women 1.3 (12/911) 2.5 (20/788) 5.6 (31/555) 13.3 (61/460) 24.6 (58/236) 30 (27/90)
men 0.7 (5/736) 1.9 (12/623) 2.7 (11/404) 8.6 (24/279) 18.5 (28/151) 37.8 (17/45)
Mathillas [24] Sweden women – – – – 23.8 (55/231) 42 (169/402)
men – – – – 20 (22/110) 27 (41/152)
Tola-Arribas [29] Spain women 1.7 (5/296) 1.7 (4/237) 10.2 (25/246) 14.1 (31/220) 27.2 (41/151) 36.8 (32/87)
men 1.2 (3/253) 1.7 (4/238) 5.9 (12/203) 12.5 (18/144) 7.4 (5/68) 14.8 (4/27)
Lucca [33] Italy women – – – 17.6 (81/461) 34.6 (168/485) 53.4 (465/871)
men – – – 11.8 (27/228) 27.8 (47/169) 36.9 (106/287)
Perquin [30] Luxembourg women 0.6 (1/172) 2.7 (5/187) 2.7 (5/186) 7.6 (11/145) 12.7 (10/79) 10 (4/40)
men 1.9 (3/159) 1.2 (2/160) 3 (4/134) 6.4 (5/78) 3.6 (1/28) 22.2 (2/9)
Total∗ (CI95%) I2 = % p women 1.1 (0.6–1.6) 2.2 (1.6–2.9) 5.6 (3.6–7.5) 13.3 (10.7–15.9) 26.4 (21.3–31.5) 38.9 (28.2–49.7)
I2 = 0 p = 0.5 I2 = 0 p = 0.9 I2 = 65 p = 0.01 I2 = 55 p = 0.04 I2 = 78 p = 0.01 I2 = 93 p = 0.01
men 0.9 (0.5–1.3) 2.1 (1.3–2.8) 4.6 (2.3–6.9) 9 (5.1–12.9) 13.9 (7.6–20.2) 31.2 (24.3–38.3)
I2 = 0 p = 0.81 I2 = 39 p = 0.13 I2 = 84 p = 0.01 I2 = 84 p = 0.01 I2 = 83 p = 0.01 I2 = 54 p = 0.03
∗Meta-analysis using random effect model.
of dementia syndromes compared to subjects in the
same age class living in the community. The higher
prevalence rates observed in women, compared to
men, in the six considered age-classes (Table 3),
confirms the well-established differential frequency
of dementia in the two sexes, due to the established
differences between the two sexes in life expectancy,
educational level, sex hormones, and cognitive
functions [37, 38].
A meta-analysis of 51 studies carried out in the
years 1980–2004 used a random effect exponential
model to investigate the effect of age and sex on
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Fig. 2. Age- and sex-specific prevalence rate in three European systematic reviews (Eurodem project [3], Lobo’s study [4], and our study).
Fig. 3. Forrest plot of the meta-analysis of data from single studies. The lower diamond in the graph represents the global cumulative
estimate.
the prevalence of dementia, and reported a 7.29%
standardized prevalence rate in subjects >60 years in
western Europe [39].
Analyzing specifically the prevalence observed in
the western Europe population, we can underline that
our data result similar to the prevalence rates reported
1478 I. Bacigalupo et al. / A Systematic Review and Meta-Analysis on the Prevalence of Dementia in Europe
Table 4
Number of studies included in the reviews according to country and diagnostic criteria
DSM IV DSM III-R DSM III CAMDEX AGECAT ICD-9
Our Study
(1993–2018)
Italy (3)
Spain (3)
Sweden (1)
United Kingdom (1)
Luxembourg (1)
Lobo et al.
(1991–1997)
[4]
Italy (1)
Spain (1)
Sweden (1)
Finland (1)
Netherlands (1)
France (1)
Denmark (1)
Spain (1)
United Kingdom (1)
Spain (1)
United Kingdom (1)
Eurodem
Project
(1980–1990)
[3]
Sweden (1)
Netherlands (1)
Finland (1)
Italy (1)
Norway (1)
Netherlands (1)
Spain (1)
United Kingdom (1)
United Kingdom (2) United Kingdom (1) Germany (1)
Note: Country (number of studies).
by Prince et al., particularly in the population aged
>90 [39]. The authors highlight that in high-income
countries the number of people with dementia will
continue to grow, in particular among the oldest [39].
The estimates provided in our studies were based
on data from 5 countries (Italy, Spain, Sweden, UK,
Luxemburg) out of the 28 (18%) included in the Euro-
pean Union.
The diagnostic criteria adopted in each study and
the geographical area where the studies were carried
out (Eurodem and our study) [3, 4] are reported in
Table 4.
Overall, previous reviews and our study were based
on 32 population studies, 13 of which were car-
ried out in the southern countries of Europe (1 in
France, 7 in Spain, and 5 in Italy), and 19 were car-
ried out the northern countries of Europe (7 in United
Kingdom, 3 in Netherlands, 3 in Sweden, 2 in Fin-
land, 1 in Denmark, 1 in Luxembourg, 1 in Norway,
and 1 in Germany) [3, 4]. The criteria used by the
different studies to diagnose dementia were widely
heterogeneous, including the DSM IV, DSM III-R,
DSM III, CAMDEX, AGECAT, and ICD-9 criteria.
The influence of using different diagnostic criteria
on the estimates of the prevalence of dementia is a
well-known issue in the scientific community [40].
The proportion of subjects diagnosed with dementia
ranges from 3.1% when using the ICD-10 criteria to
29.1% when using the DSM III criteria [40], while a
13.7% prevalence rate was obtained when using the
DSM IV criteria [40].
The different diagnostic criteria include different
combinations of impairment in cognitive, emotional,
and social abilities and reflect an emphasis on dif-
ferent clinical features or on a particular cause [40].
In particular, the different relevance of the evaluation
of short and long-term memory in the application of
diagnostic criteria is a well-established issue [40].
An interesting study on subjects aged 90–100 years
reported a wide variability in the estimated prevalence
rates of dementia according to different diagnostic
criteria, with a 47.1% rate according to DSM III-R
criteria, a 41.2% rate according to DSM IV criteria,
a 29.4% according to ICD 10 criteria, and a 38.2%
rate according to CAMDEX criteria [41].
All prevalence rates reported in previously pub-
lished studies are considerably affected by a
consistent heterogeneity due to methodological dif-
ferences in the sampling criteria, study design,
response rate, diagnostic tools, and procedures [3, 4].
When carrying out our systematic review, we took
into account two of the main possible sources of
heterogeneity, that is, the diagnostic criteria and the
methodological quality of the study.
To our knowledge, none of the previously pub-
lished studies considered the effect of methodological
issues in estimating the prevalence of dementia [3, 4].
In addition to the relevance of the diagnostic criteria,
another issue to be taken into consideration is the need
to carry out high-quality studies on the prevalence of
dementia in each country.
Therefore, to minimize heterogeneity and account
for possible limitations due to methodological issues,
we restricted our analyses only to high-quality studies
adopting the same diagnostic criteria (i.e., DSM IV).
However, a wide heterogeneity across studies in the
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reported prevalence rates of dementia was observed
in subjects aged >75 years (Table 3). This result might
be partially due to the presence of a subgroup of insti-
tutionalized subject in some of the included studies,
and by the lack of the measure of the case-finding
procedure. In fact, the use of the ADI tool does not
allow to assess the specific validity of questionnaire
and/or clinical scale used in the assessed study within
the diagnostic process.
Estimating the specific prevalence rate of demen-
tia in each country is essential to adequately plan
prevention strategies, as potential differences in the
prevalence of dementia could be due to differences in
potentially modifiable risk factors [42, 43]. Moreover,
designing specific, high-quality studies is crucial to
obtain strong, reliable estimates on which to plan
public health interventions and policies. A system-
atic review of studies on the prevalence of dementia
in Italy, reported a slight tendency of the method-
ological quality, assessed with the ADI tool, of these
studies to improve over time [44].
A systematic review of studies published in the
years 1990–2007 reported that the quality of the stud-
ies performed in central and eastern areas of Europe
was significantly lower when compared to the stud-
ies performed in western Europe [45, 46]. In the
World Alzheimer Report 2015, the authors them-
selves underline the possible presence of errors due
to the relatively poor quality of several of the consid-
ered studies [47]. In this context, the ADI criteria may
be a useful tool to improve the quality standards in
this field. They have already been used to assess the
quality of the studies included in the systemic review
and meta-analysis carried out by Prince et al. [39],
and they have also been used to evaluate the qual-
ity of some prevalence studies carried out in Italy
[44]. However, the ADI criteria have never been used
as inclusion criteria within a review to identify the
studies on which to estimate a prevalence rate.
From a public health point of view, monitoring
the frequency of dementia is essential to plan and
organize health and social services and to assess
the impact of potential preventive strategies. For
these reasons, the recommendations on epidemio-
logical issue provided by the ALCOVE project may
be extremely useful [6]. They focused on 5 spe-
cific issues: 1) future studies on the prevalence of
dementia should be performed with the aim of meet-
ing the highest methodological quality as defined by
the ADI 2009 report [7]; 2) the use of the DSM
IV and NINCD-ADRDA criteria for the diagnosis
of dementia within epidemiological studies should
be promoted, as these are the only criteria validated
with post-mortem data; 3) the use of the NIA cri-
teria and the Alzheimer’s Association criteria within
incidence and prevalence studies should be promoted
[48]; 4) further studies on the prevalence and inci-
dence of dementia in subjects aged ≤65 years should
be promoted to define its frequency in this age class;
and 5) further studies should be promoted to identify
possible decreases in the incidence of dementia, as
suggested by some recent studies [6].
The limitation of our work is to have used only
MEDLINE/PubMed as a database for bibliographic
research, but we decided to follow the same method-
ology of EuroCode and Alcove projects.
In conclusion considering also the recent creation
of the Global Dementia Observatory (GDO) of the
WHO [49], we deem it extremely relevant to provide
high-quality estimates of the prevalence of dementia
in each specific country. Considering the significant
implications in planning social and public policies,
a reappraisal of the global dimension of dementia
is urgent [45]. Only in Italy, the estimated number
of cases of dementia in 2018 results about 1 million
when applying the age- and sex-specific prevalence
pooled rates of dementia reported by Lobo et al. [4],
while the number increases to 1 million and 60,000
cases when applying the estimates provided by the
present systematic review.
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